JintzBio Co., Ltd. won the top award in the Anticancer New Drug category at the “2026 National Industrial Awards.”

Established in 2020, JintzBio is a biotechnology company specializing in anticancer agents and treatments for rare diseases, and is leading innovation in the field of non-small cell lung cancer. From its early days, the company has built its own research and development capabilities and a global collaboration network, focusing on the rapid and precise development of therapeutics in areas with high levels of unmet clinical need. In particular, by securing both an oncology pipeline and an AI-based new drug development platform, it has gained recognition for its technological capabilities and growth potential, and was selected in 2025 as a “Baby Unicorn Company” by the Ministry of SMEs and Startups, thereby demonstrating its competitiveness in the market.

One of JintzBio’s flagship pipelines is “JIN-A04 (YH42946),” a HER2-targeted therapy for non-small cell lung cancer, which was licensed out to Yuhan Corporation in 2023 in a deal worth approximately KRW 430 billion. This is regarded as a case that simultaneously proves JintzBio’s global technology transfer capabilities and its commercialization potential.

The next-generation EGFR-targeted anticancer drug “JIN-A02,” currently under development, is an innovative new drug designed to overcome resistance issues associated with existing therapies. Research results have been continuously presented at major international academic conferences, including the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the World Conference on Lung Cancer (WCLC), earning recognition for its academic and clinical value. In addition, it was designated as an orphan drug by the Ministry of Food and Drug Safety in 2025 and was consecutively selected for projects by the Korea Drug Development Fund (KDDF) and the Seoul Business Agency’s Bio-Medical Technology Commercialization program, thereby providing authoritative verification of its research and development capabilities and technological excellence.

In particular, JIN-A02 is a next-generation EGFR inhibitor designed to address complex resistance mutations, including C797S, with the goal of securing both selectivity and efficacy across various mutational contexts. Preclinical studies have confirmed its antitumor effects, including in brain metastasis models, indicating its potential as a new treatment option for lung cancer going forward.

Popular News